The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
Abstract A potential strategy to cure HIV-1 infection is to use latency reversing agents (LRAs) to eliminate latent reservoirs established in resting CD4+ T (rCD4+) cells. As no drug has been shown to be completely effective, finding new drugs and combinations are of increasing importance. We studie...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Portfolio
2017-05-01
|
| Col·lecció: | Scientific Reports |
| Accés en línia: | https://doi.org/10.1038/s41598-017-02634-y |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|